Irritable Bowel Syndrome Identifying Genetic Defect

Galapagos provides status update for GSK2586184, (GLPGF) announced today that GSK has updated the development status for GSK2586184, involving three clinical studies in psoriasis, lupus, and .

GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ inflammation alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK up to EURO34M in additional milestones, plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.

All dosing of patients in the Phase 2 study in psoriasis has completed. Topline efficacy and safety results from this study are expected in the first half of 2014. Galapagos is eligible to receive a milestone payment from GSK in the event that GSK achieves a successful Proof-of-Concept in patients treated with GSK2586184. The psoriasis study was designed to recruit 64 patients, with treatment up to 12 weeks.

Read: Galapagos provides status update for GSK2586184

 

About Robert Hill

I founded IDEAS Intestinal Disease Education and Awareness Society, from my home base in Vancouver, British Columbia. Intestinal Disease Education and Awareness Society IDEAS is established to raise public awareness of intestinal diseases in order to help remove the stigmas associated with these illnesses. The programs of IDEAS help children, youth and young adults learn to live full lives, find acceptance and gain confidence.

Leave a Reply